Q2 FY24 Earnings Results
Q2 FY24 earnings, Jul–Sep 2023: 5,345 Indian listed companies have reported; median profit growth is 0.0% on last year. Quarter ended 30 Sep 2023.
Reported
5,345
companies
Profit breadth
44% / 46%
grew / declined · 338 comparable
Median sales YoY
+8.0%
across all reporters
Median profit YoY
0.0%
across all reporters
Beat / missed
0 / 0
of 0 covered
Strongest / weakest
Petroleum Products +200.0%
Energy −157.9%
median profit growth, 10+ reporters
Clear filters 201–232 of 232
| Company | Revenue (₹ Cr) | Profit (₹ Cr) | Per share | 8Q profit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Symbol | Sector | Reported | YoY | QoQ | Reported | YoY | EPS | vs consensus | Trend |
 MEDINOVADIAGNOSTICSERVICELTD Medinova Diagnostic Services Ltd | Healthcare | 3 | up+12.1% | up+18.6% | 1 | up+83.3% | 0.66 | No estimate | |
| Medinova Diagnostic Services Ltd | Healthcare | 3 | up+12.1% | up+18.6% | 1 | up+83.3% | 0.66 | No estimate | |
 MEDICAPQ Medi Caps Ltd | Healthcare | 2 | n/a | up+10,550.0% | 2 | n/a | 1.55 | No estimate | |
 COLINZLABORATORIESLTD | Healthcare | 2 | n/a | down−5.8% | 0 | n/a | 0.48 | No estimate | |
 GANGAPHARMACEUTICALSLTD | Healthcare | 1 | down−2.2% | n/a | 0 | down−33.3% | 0.05 | No estimate | |
 DESHRAKSHAKAUSHDHALAYALTD | Healthcare | 1 | n/a | down−24.3% | 0 | n/a | 0.20 | No estimate | |
 AMBALALSA Ambalal Sarabhai Enterprises Ltd | Healthcare | 1 | n/a | down−52.9% | 1 | n/a | 0.07 | No estimate | |
 MURAEORGANISORLTD | Healthcare | 0 | down−94.0% | down−74.9% | −1 | down−2,275.0% | −0.01 | No estimate | |
| RUBRAMEDICAMENTSLTD Centuple Global Ltd | Healthcare | 0 | n/a | up+45.0% | 0 | n/a | 0.48 | No estimate | |
 ORTINGLOBE Ortin Global Ltd | Healthcare | 0 | n/a | down−82.8% | −1 | n/a | −1.38 | No estimate | |
 GENOMICVALLEYBIOTECHLTD | Healthcare | 0 | n/a | up+16.7% | 0 | n/a | 0.07 | No estimate | |
 SHYAMAINFOLTD Shyama Computronics and Services Ltd | Healthcare | 0 | n/a | 0.0% | 0 | n/a | 0.01 | No estimate | |
 TAKE Take Ltd | Healthcare | 0 | n/a | down−98.6% | −2 | n/a | −0.10 | No estimate | |
 CELESTIAL Celestial Biolabs Ltd | Healthcare | 0 | 0.0% | up+100.0% | 0 | n/a | −0.01 | No estimate | |
 TRANSCHEMLTD | Healthcare | 0 | n/a | n/a | 1 | n/a | 0.79 | No estimate | |
 CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | 2.93 | No estimate | |
 TRIOCHEMPRODUCTSLTD | Healthcare | 0 | n/a | n/a | −1 | n/a | −42.04 | No estimate | |
| GENESISIBRCINDIALTD CCME Global Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.02 | No estimate | |
 GUJINJECLTD Gujarat Inject (Kerala) Ltd | Healthcare | 0 | n/a | down−100.0% | 0 | n/a | 0.00 | No estimate | |
 KABRADRUGSLTD | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.30 | No estimate | |
 BACILPHARMALTD | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.02 | No estimate | |
 PHARMAIDSPHARMACEUTICALSLTD | Healthcare | 0 | n/a | n/a | −1 | n/a | −0.23 | No estimate | |
 KAMRONLABORATORIESLTD Adline Chem Lab Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.09 | No estimate | |
 WELCUREDRUGSPHARMACEUTICALSLTD Welcure Drugs & Pharmaceuticals Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.01 | No estimate | |
 BHARATIMMUNOLOGICALSBIOLOGICALSCORPORATIONLTD Bharat Immunological & Biological Corporation Ltd | Healthcare | 0 | down−100.0% | n/a | −5 | n/a | −1.14 | No estimate | |
| REKVINALABORATORIESLTD Rekvina Labs Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.01 | No estimate | |
| VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.06 | No estimate | |
| RAYMEDLABSLTD Cresanto Global Limited | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.05 | No estimate | |
| MPS Pharmaa Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.09 | No estimate | |
 TRANSPACTENTERPRISESLTD | Healthcare | 0 | n/a | n/a | 0 | down−250.0% | −0.78 | No estimate | |
 Transchem Ltd | Healthcare | 0 | n/a | n/a | 1 | n/a | 0.79 | No estimate | |
| Harleystreet Pharmaceuticals Ltd(merged) | Healthcare | — | n/a | n/a | 127 | n/a | 4.06 | No estimate | |
About Q2 FY24 earnings data
When are Q2 FY24 results announced?
Q2 FY24 covers the Jul–Sep 2023 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q2 FY24 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No analyst consensus was available for Q2 FY24, so no beat/miss verdict is shown. Revenue and profit growth are taken from reported results and cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q2 FY24?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.
Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.